A Comparative Study Of Zoledronic Acid And Risedronate Sodium In The Treatment Of Female With Osteoporosis

Objective:To retrospectively evaluate the effects of zoledronic acid and risedronate sodium on bone mineral density in female patients with osteoporosis,in order to understand the efficacy and safety of the two drugs,and to provide better clinical decision-making for the drug treatment of female patients with osteoporosis.Method:Retrospective analysis was conducted to determine the Bone Mineral Density(BMD)of female patients who visited Yibin First People’s Hospital from January 2013 to December 2020 using Dual Energy X-Ray Ababsorptiometry(DXA)and identified as osteoporosis.All patients were given "Calcium Carbonate D3 Tablets 0.6g+Calcitriol Capsules 0.25μg"orally every day.Patients were divided into two groups according to different medications:zoledronic acid group(69 cases);In the risedronate sodium group(77 cases),BMD was measured in the lumbar spine and left femoral neck of patients who had been treated for 1,2 and 3 years.BMD data and the incidence of adverse reactions after treatment were collected and recorded,and the effects of different durations of the two drugs on BMD in osteoporosis female patients were compared and analyzed.Results:In the zoledronic acid group,BMD of lumbar spine and left femoral neck increased after one,two and three times of medication compared with before medication,and the BMD was statistically significant.The BMD of the lumbar spine and the left femoral neck in the risedronate sodium group increased after 1,2 and 3 years of treatment compared with that before treatment,and the difference was statistically significant.The BMD of the lumbar spine and the left femoral neck increased more significantly in the zoledronic acid group after one,two and three times of medication than in the sodium seredronate group after one,two and three years of medication,with statistical significance.Both zoledronic acid and risedronate sodium could increase the BMD of lumbar spine and left femoral neck in primary and secondary osteoporosis,but the differences were not statistically significant.In the comparative analysis of adverse reactions between the zoledronic acid group and the risedronic sodium group,it was found that the incidence of fever,myalgia,arthralgia and influenza-like symptoms one year after the use of zoledronic acid group was higher than that of the risedronic sodium group,and the difference was statistically significant,while there was no significant difference in other adverse reactions.Conclusion:The zoledronic acid group and risedronic acid sodium group had good curative effect on osteoporosis in female.Therefore,in this study,the zoledronic acid group was better than the risedronic sodium group in improving the bone mineral density of female with osteoporosis,and could be used as the first choice for the treatment of female with osteoporosis.However,the incidence of adverse reactions of zoledronic acid group was higher than that of risedronic acid group in fever,myalgia,arthralgia and influenza-like symptoms.Regular monitoring of bone mineral density and the occurrence of adverse reactions should be conducted during the use of zoledronic acid group.